Molika Ashford

The company said the results highlight precision oncology implementation challenges and its test's ability to help overcome these issues.

Both the MRD test, BR Prophet, and a six-cancer screening assay, BR Predict, are slated for launch in China next year, initially for contracted hospital customers.

Based on promising early results, the company is now conducting a larger case-control study to lock in a classifier for prospective validation in an intended-use population.

Researchers demonstrated that detection of single and clustered circulating trophoblasts could reliably differentiate placenta accreta from normal controls and other disorders, even early in gestation.

The move opens the first non-oncology application for Oncocyte, which acquired the relevant cell-free DNA technology in its merger with Chronix this April.

The firm said it will release its colorectal cancer test as an LDT next year and has reorganized its leadership to support future growth in the cancer screening market.

The company is working with three institutions to recruit about 1,200 case-control participants for its validation study, with plans to launch an LDT next year.

The company reported significant momentum in test volumes for the second quarter of this year as new publications shore up utility evidence and open new applications.

The company is providing its 400-gene test through a physician-involved DTC model akin to Color and Invitae, but with content across a much larger swath of disease and health.

The technology, developed by researchers at Stanford, showed strong performance in a new study of lymphoma, and early data for solid tumors is already available.